Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Moxifloxacin prophylaxis during continuous silicone hydrogel contact lens wear
ACTRN12610000920099Phase 3Completed
- Sponsor
- Brien Holden Vision Institute
- Start
- Nov 2010
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of moxifloxacin in contact lens-related inflammatory ocular adverse events (CIE) (2 arms), sponsored by Brien Holden Vision Institute. Primary endpoint: Reduction of contact lens-related inflammatory ocular adverse events. Started Nov 2010; status: completed.
02
Drugs
moxifloxacin
03
Conditions
contact lens-related inflammatory ocular adverse events (CIE)
Beyond the preview
Go deeper on ACTRN12610000920099.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12610000920099.